MGMT and glioblastoma: Previous studies showed that the coexistence of IDHmut and MGMTmet significantly prolonged the overall survival of glioblastoma patients who received temozolomide and radiation therapy (Yang et al., 2015; Li et al., 2016), and IDH mutation and MGMT promoter methylation were independent predictive factors for pseudoprogression disease (Li et al., 2016).